Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Adults with plantar heel pain¹
1 finding from 1 review
Intervention not reported
Serious adverse events · people with pressure ulcers
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children with chronic asthma
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children with chronic asthma
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic asthma
LABA + ICS showed no clear difference in serious adverse events compared with LTRA + ICS (moderate certainty).
1 finding from 1 review
Systemic adverse events at · people with eczema
1 finding from 1 review
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid showed no clear difference in systemic adverse events at compared with intravitreal anti‐VEGF (low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious adverse events · people with pressure ulcers
The intervention may leads to higher non‐serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events 49 weeks · adults with asthma
The intervention leads to lower any adverse events 49 weeks (high certainty).
1 finding from 1 review
Any adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in any adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐5 mAb (mepolizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Adverse events ‐ nasopharyngitis, including sore throat · patients with chronic rhinosinusitis with nasal polyps
Anti‐IgE mAb (omalizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found